Home › Trials › NCT06163924
Clinical trial Recruiting at 1 site Observational Ages 18 and up Men only

Multidisciplinary care for cardiovascular risk in prostate cancer patients on hormone therapy

Official title: To Investigate the Effect of Multidisciplinary Care Approach on Cardiovascular Risk Modification in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Run by Chinese University of Hong Kong · NCT06163924 · Data updated 2026-11-12

This study is testing if a team-based approach to care can help men with prostate cancer on hormone therapy lower their heart health risks.

More Prostate Cancer trials

Quick facts

Study typeObservational
Ages18 Years and up
SexMen only
Enrollment300 (estimated)
SponsorChinese University of Hong Kong
Academic / other
Locations1 site (Hong Kong)
StatusRecruiting
StartedDecember 10, 2023
Main results expectedDecember 31, 2028
Study endsMarch 31, 2029
Registry record updatedOctober 28, 2026
Trial IDNCT06163924 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adult men aged 18-80 with histologically proven or clinically diagnosed prostate cancer who are planning to receive ADT for at least one year.

Probably not a fit

Patients with established major atherosclerotic cardiovascular disease or those who have received prior hormone therapy within the last year may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the impact of a multidisciplinary care approach on cardiovascular risk modification in patients with prostate cancer who are receiving androgen deprivation therapy (ADT). It seeks to gather data on cardiovascular risk factors, monitoring, and treatment strategies to better understand how to mitigate the adverse cardiovascular effects associated with ADT. The study will involve adult men diagnosed with prostate cancer who are planning to undergo ADT for at least one year, focusing on their cardiovascular health throughout the treatment period.

Why it matters

Potential benefit: If successful, this study could lead to improved cardiovascular health and reduced morbidity for prostate cancer patients undergoing ADT.

How similar studies have gone: While there is limited data on the specific approach of this study, similar studies have indicated the importance of cardiovascular monitoring in patients undergoing ADT, suggesting potential for positive outcomes.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult men ≥18 years old
* With histological proven prostate cancer or clinically diagnosed to have prostate cancer,
* Planned for ADT for at least 1 year

Exclusion Criteria:

* Prior neoadjuvant or adjuvant hormone therapy within 1 year before
* Refuse or unable to give written informed consent
* Participation in an investigational program with interventions outside of routine clinical practice

Where it's running

  • The Chinese University of Hong Kong
    Hong Kong, Hong Kong     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Cardiovascular Risk 122Prostate Cancer 1464Chinese University of Hong Kong 279
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.